- Home
- PRT vs KLRS Comparison
PRT vs KLRS Comparison
Compare PRT & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- KLRS
- Stock Information
- Founded
- PRT 2017
- KLRS 2019
- Country
- PRT United States
- KLRS United States
- Employees
- PRT N/A
- KLRS N/A
- Industry
- PRT Oil & Gas Production
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRT Energy
- KLRS Health Care
- Exchange
- PRT Nasdaq
- KLRS Nasdaq
- Market Cap
- PRT 47.7M
- KLRS 46.0M
- IPO Year
- PRT N/A
- KLRS N/A
- Fundamental
- Price
- PRT $3.95
- KLRS $7.68
- Analyst Decision
- PRT
- KLRS Strong Buy
- Analyst Count
- PRT 0
- KLRS 2
- Target Price
- PRT N/A
- KLRS $23.00
- AVG Volume (30 Days)
- PRT 35.1K
- KLRS 224.3K
- Earning Date
- PRT 11-12-2025
- KLRS 11-15-2025
- Dividend Yield
- PRT 10.75%
- KLRS N/A
- EPS Growth
- PRT 1.16
- KLRS N/A
- EPS
- PRT 0.44
- KLRS N/A
- Revenue
- PRT $6,314,770.00
- KLRS N/A
- Revenue This Year
- PRT N/A
- KLRS N/A
- Revenue Next Year
- PRT N/A
- KLRS N/A
- P/E Ratio
- PRT $8.93
- KLRS N/A
- Revenue Growth
- PRT 1.82
- KLRS N/A
- 52 Week Low
- PRT $3.26
- KLRS $2.14
- 52 Week High
- PRT $4.63
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- PRT 52.30
- KLRS 67.13
- Support Level
- PRT $3.84
- KLRS $4.41
- Resistance Level
- PRT $3.99
- KLRS $8.80
- Average True Range (ATR)
- PRT 0.08
- KLRS 0.89
- MACD
- PRT 0.01
- KLRS 0.23
- Stochastic Oscillator
- PRT 71.23
- KLRS 69.46
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.